{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:05:48Z","timestamp":1791572748512,"version":"4.3.4"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["UG1DA040317"],"award-info":[{"award-number":["UG1DA040317"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["75N9501920013; 7595020F0005"],"award-info":[{"award-number":["75N9501920013; 7595020F0005"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pharmacists play a key role in combating the opioid-related overdose epidemic in the United States (US), but little is known about their experience and willingness to deliver preventive services for opioid use disorder (OUD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>This study seeks to identify correlates of pharmacists\u2019 concerns about drug use problems (prescription drug misuse\/use disorder and illicit drug use\/use disorder) as well as their practice experience delivering preventive services for OUD (e.g., asked about opioid use, provided advice, made a referral) and willingness to provide services to patients with drug use problems.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>An online survey of licensed US pharmacists was conducted. Participants were recruited from Community Pharmacy Enhanced Services Networks (CPESN) and state pharmacist associations (<jats:italic>N<\/jats:italic>\u2009=\u20091146).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Findings<\/jats:title>\n                <jats:p>Overall, 75% of surveyed pharmacists indicated having concerns about opioid use problems, and 62% had concerns about non-opioid drug use problems at their pharmacies. Pharmacists who were White, practiced at a rural location, worked at a chain pharmacy, had not received opioid-related training in the past year, or practiced screening patients for opioid use had elevated odds of perceiving concerns about opioid use problems in their practice settings. Pharmacists who were White, practiced at a rural location, or had not received opioid-related training in the past year had elevated odds of perceiving concerns about non-opioid (illicit) drug use problems. Being male, being White, or having received opioid-related training were associated with increased odds of screening patients for opioid use problems. Being White, having practiced at a rural location (vs. an urban location), being a pharmacy owner\/manager, or having received opioid-related training were associated with increased odds of delivering opioid-related advice\/intervention. Being male or having received opioid-related training were associated with increased odds of making a referral to OUD treatment. Finally, being male, being White, having practiced pharmacy services for under 6 years, having received opioid-related training for 2\u00a0h in the past year, or having performed OUD-related preventive services (asked about opioid use, provided advice, or made a referral) were associated with increased levels of commitment\/readiness for providing care to patients with drug use problems.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The overall findings highlight pharmacists\u2019 involvement with OUD preventive services. It is critical to promote opioid-related preventive service training for pharmacists and provide incentives\/tools to help initiate a structured practice of delivering such preventive services.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-024-00519-w","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:02:30Z","timestamp":1733097750000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacy-based preventive services for opioid use disorder: a survey of U.S. pharmacists"],"prefix":"10.1186","volume":"19","author":[{"given":"Li-Tzy","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacquie","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Hefner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Schactman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Hagemeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail G.","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Mannelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"519_CR1","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics. 2023. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm"},{"key":"519_CR2","doi-asserted-by":"publisher","unstructured":"Spencer MR, Mini\u00f1o AM, Warner M. Drug Overdose Deaths in the United States, 2001\u20132021. NCHS Data Brief, no 457. Hyattsville, MD: National Center for Health Statistics 2022. https:\/\/doi.org\/10.15620\/cdc:122556","DOI":"10.15620\/cdc:122556"},{"issue":"4","key":"519_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3810\/pgm.2013.07.2684","volume":"125","author":"JA Gudin","year":"2013","unstructured":"Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and\/or alcohol use. Postgrad Med. 2013;125(4):115\u201330.","journal-title":"Postgrad Med"},{"issue":"1","key":"519_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsat.2014.08.004","volume":"48","author":"RK McHugh","year":"2015","unstructured":"McHugh RK, Nielsen S, Weiss RD. Prescription drug abuse: from epidemiology to public policy. J Subst Abuse Treat. 2015;48(1):1\u20137.","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"519_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jsr.2012.08.009","volume":"43","author":"LJ Paulozzi","year":"2012","unstructured":"Paulozzi LJ. Prescription drug overdoses: a review. J Saf Res. 2012;43(4):283\u20139.","journal-title":"J Saf Res"},{"key":"519_CR6","doi-asserted-by":"crossref","unstructured":"Rudd RA. Increases in drug and opioid-involved overdose deaths\u2014United States, 2010\u20132015. MMWR. Morbidity and mortality weekly report. 2016;65.","DOI":"10.15585\/mmwr.mm655051e1"},{"issue":"1","key":"519_CR7","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1331\/JAPhA.2014.13101","volume":"54","author":"American Pharmacists Association (APhA)","year":"2014","unstructured":"American Pharmacists Association (APhA). Pharmacists\u2019 role in addressing opioid abuse, addiction, and diversion. J Am Pharmacists Association. 2014;54(1):e5\u201315.","journal-title":"J Am Pharmacists Association"},{"issue":"2","key":"519_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/jac5.1171","volume":"3","author":"JP Bratberg","year":"2020","unstructured":"Bratberg JP, Smothers ZP, Collins K, Erstad B, Ruiz Veve J, Muzyk AJ. Pharmacists and the opioid crisis: a narrative review of pharmacists\u2019 practice roles. J Am Coll Clin Pharm. 2020;3(2):478\u201384. https:\/\/doi.org\/10.1002\/jac5.1171. https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/abs\/.","journal-title":"J Am Coll Clin Pharm"},{"issue":"4","key":"519_CR9","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1177\/08897077231203849","volume":"44","author":"JB Jarrett","year":"2023","unstructured":"Jarrett JB, Bratberg J, Burns AL, Cochran G, DiPaula BA, Legreid Dopp A, Elmes A, Green TC, Hill LG, Homsted F, Hsia SL, Matthews ML, Ghitza UE, Wu LT, Bart G. Research priorities for expansion of opioid use disorder treatment in the Community Pharmacy. Subst Abus. 2023;44(4):264\u201376.","journal-title":"Subst Abus"},{"issue":"3","key":"519_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2146\/sp140002","volume":"71","author":"American Society of Health-System Pharmacists (ASHP)","year":"2014","unstructured":"American Society of Health-System Pharmacists (ASHP). ASHP statement on the pharmacist\u2019s role in substance abuse prevention, education, and assistance. Am J health-system Pharm. 2014;71(3):243\u20136.","journal-title":"Am J health-system Pharm"},{"issue":"10","key":"519_CR11","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.5688\/aj7410s11","volume":"74","author":"PW Jungnickel","year":"2010","unstructured":"Jungnickel PW, Desimone EM, Kissack JC, Lawson LA, Murawski MM, Patterson BJ, Rospond RM, Scott DM, Athay J, AACP Special Committee on Substance Abuse and Pharmacy Education. Report of the AACP Special Committee on Substance Abuse and Pharmacy Education. Am J Pharm Educ. 2010;74(10):S11. https:\/\/doi.org\/10.5688\/aj7410s11. PMID: 21436899; PMCID: PMC3058467.","journal-title":"Am J Pharm Educ"},{"issue":"11","key":"519_CR12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ptdy.2018.10.021","volume":"24","author":"L Haberkorn","year":"2018","unstructured":"Haberkorn L. Easy to reach and ready to help: not just dispensing medication. Pharm Today. 2018;24(11):38\u20139.","journal-title":"Pharm Today"},{"issue":"4","key":"519_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.sapharm.2018.06.006","volume":"15","author":"KA Look","year":"2019","unstructured":"Look KA, Kile M, Morgan K, Roberts A. Community pharmacies as access points for addiction treatment. Res Social Adm Pharm. 2019;15(4):404\u20139.","journal-title":"Res Social Adm Pharm"},{"key":"519_CR14","unstructured":"National Association of Chain Drug Stores (NACDS). 2013. NACDS Impact Report. Community pharmacy fills gaps in access and affordability for patients, payers. March 2013, page 1\u20135. http:\/\/rximpact.nacds.org\/pdfs\/rximpact_0313.pdf"},{"key":"519_CR15","unstructured":"Centers for Disease Control and Prevention (CDC). 2021. Prescription Drug Monitoring Programs (PDMPs). https:\/\/www.cdc.gov\/drugoverdose\/pdmp\/index.html#:~:text=When%20pharmacists%20dispense%20controlled%20substances,%E2%80%9D%20i.e.%2C%20under%20five%20minutes"},{"key":"519_CR16","doi-asserted-by":"publisher","unstructured":"Offu OF, Visram S, Rathbone AP, Lindsey L. Factors influencing pharmacists\u2019 roles in preventing prescription and over-the-counter opioid misuse: a systematic review and narrative synthesis. Int J Pharm Pract 2023 Dec 27:riad090. https:\/\/academic.oup.com\/ijpp\/advance-article\/doi\/https:\/\/doi.org\/10.1093\/ijpp\/riad090\/7502464","DOI":"10.1093\/ijpp\/riad090\/7502464"},{"key":"519_CR17","doi-asserted-by":"crossref","unstructured":"Bratberg J, Pharmacy. Addressing substance use in the 21st century. Subst Abuse 2019;40(4):421-434.","DOI":"10.1080\/08897077.2019.1694618"},{"key":"519_CR18","doi-asserted-by":"crossref","unstructured":"Griffin M, Martino RJ, LoSchiavo C, Comer-Carruthers C, Krause KD, Stults CB, Halkitis PN. Ensuring survey research data integrity in the era of internet bots. Qual Quantity 2022;56(4):2841-2852.","DOI":"10.1007\/s11135-021-01252-1"},{"key":"519_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/add.13675","volume":"112","author":"TF Babor","year":"2017","unstructured":"Babor TF, Del Boca F, Bray JW. Screening, brief intervention and referral to treatment: implications of SAMHSA\u2019s SBIRT initiative for substance abuse policy and practice. Addiction. 2017;112:110\u20137.","journal-title":"Addiction"},{"issue":"5","key":"519_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/ADM.0000000000000525","volume":"13","author":"BC Shonesy","year":"2019","unstructured":"Shonesy BC, Williams D, Simmons D, Dorval E, Gitlow S, Gustin RM, Screening. Brief intervention, and referral to treatment in a Retail Pharmacy setting: the Pharmacist\u2019s role in identifying and addressing risk of Substance Use Disorder. J Addict Med. 2019;13(5):403\u20137.","journal-title":"J Addict Med"},{"issue":"2","key":"519_CR21","first-page":"107","volume":"103","author":"K Lin","year":"2021","unstructured":"Lin K. Screening for unhealthy drug use: Recommendation Statement. Am Family Phys. 2021;103(2):107\u201312.","journal-title":"Am Family Phys"},{"key":"519_CR22","doi-asserted-by":"crossref","unstructured":"Hagemeier NE, Murawski MM, Lopez NC, Alamian A, Pack RP. Theoretical exploration of Tennessee community pharmacists\u2019 perceptions regarding opioid pain reliever abuse communication. Res Social Adm Pharm 2014 May-Jun;10(3):562-75.","DOI":"10.1016\/j.sapharm.2013.07.004"},{"issue":"7","key":"519_CR23","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1111\/add.15353","volume":"116","author":"LT Wu","year":"2021","unstructured":"Wu LT, John WS, Ghitza UE, Wahle A, Matthews AG, Lewis M, Hart B, Hubbard Z, Bowlby LA, Greenblatt LH, Mannelli P. Pharm-OUD-Care Collaborative investigators. Buprenorphine physician-pharmacist collaboration in the management of patients with opioid use disorder: results from a multisite study of the National drug abuse treatment clinical trials network. Addiction. 2021;116(7):1805\u201316.","journal-title":"Addiction"},{"issue":"2","key":"519_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/add.15641","volume":"117","author":"LT Wu","year":"2022","unstructured":"Wu LT, John WS, Morse E, Adkins S, Pippin J, Brooner R, Schwartz RP. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial. Addiction. 2022;117(2):444\u201356.","journal-title":"Addiction"},{"issue":"1","key":"519_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13011-023-00563-w","volume":"18","author":"LT Wu","year":"2023","unstructured":"Wu LT, Mannelli P, John WS, Anderson A, Schwartz RP. Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff. Subst Abuse Treat Prev Policy. 2023;18(1):55.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"519_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13722-023-00399-6","volume":"18","author":"LT Wu","year":"2023","unstructured":"Wu LT, John WS, Mannelli P, Morse ED, Anderson A, Schwartz RP. Patient perspectives on community pharmacy administered and dispensing of methadone treatment for opioid use disorder: a qualitative study in the U.S. Addict Sci Clin Pract. 2023;18(1):45.","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"519_CR27","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1360-0443.2006.01686.x","volume":"102","author":"H Watson","year":"2007","unstructured":"Watson H, Maclaren W, Kerr S. Staff attitudes towards working with drug users: development of the drug problems perceptions Questionnaire. Addiction. 2007;102(2):206\u201315.","journal-title":"Addiction"},{"key":"519_CR28","unstructured":"CPESN. 2023. About CPESN USA. https:\/\/cpesn.com\/about-cpesn-usa#:~:text=CPESN%20USA%20is%20America\u2019s%20first,fourth%20largest%20single%20contracting%20organization."},{"key":"519_CR29","unstructured":"Federal register 2021. Eighth Amendment to Declaration Under the Public Readiness and Emergency Preparedness Act for Medical Countermeasures Against COVID-19. https:\/\/www.federalregister.gov\/documents\/2021\/08\/04\/2021-16681\/eighth-amendment-to-declaration-under-the-public-readiness-and-emergency-preparedness-act-for"},{"issue":"1","key":"519_CR30","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/j.sapharm.2020.04.002","volume":"17","author":"M Aruru","year":"2021","unstructured":"Aruru M, Truong HA, Clark S. Pharmacy emergency preparedness and response (PEPR): a proposed framework for expanding pharmacy professionals\u2019 roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond. Res Social Administrative Pharm. 2021;17(1):1967\u201377.","journal-title":"Res Social Administrative Pharm"},{"key":"519_CR31","unstructured":"SAS Institute Inc. 2013."},{"issue":"1","key":"519_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/jrh.12328","volume":"35","author":"CH Andrilla","year":"2019","unstructured":"Andrilla CH, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113\u201321.","journal-title":"J Rural Health"},{"key":"519_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2147\/SAR.S18969","volume":"2","author":"LT Wu","year":"2011","unstructured":"Wu LT, Woody GE, Yang C, Mannelli P, Blazer DG. Differences in onset and abuse\/dependence episodes between prescription opioids and heroin: results from the national epidemiologic survey on Alcohol and related conditions. Subst Abuse Rehabilitation. 2011;2:77\u201388.","journal-title":"Subst Abuse Rehabilitation"},{"issue":"8","key":"519_CR34","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2105\/AJPH.2015.302664","volume":"105","author":"CM Jones","year":"2015","unstructured":"Jones CM, Campopiano M, Baldwin G, McCance-Katz E. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105(8):e55\u201363.","journal-title":"Am J Public Health"},{"issue":"8","key":"519_CR35","doi-asserted-by":"publisher","first-page":"e2226544","DOI":"10.1001\/jamanetworkopen.2022.26544","volume":"5","author":"PT Korthuis","year":"2022","unstructured":"Korthuis PT, Cook RR, Foot CA, Leichtling G, Tsui JI, Stopka TJ, Leahy J, Jenkins WD, Baker R, Chan B, Crane HM. Association of methamphetamine and opioid use with nonfatal overdose in rural communities. JAMA Netw open. 2022;5(8):e2226544.","journal-title":"JAMA Netw open"},{"issue":"11","key":"519_CR36","doi-asserted-by":"publisher","first-page":"e2342222","DOI":"10.1001\/jamanetworkopen.2023.42222","volume":"6","author":"DB Hoover","year":"2023","unstructured":"Hoover DB, Korthuis PT, Waddell EN, et al. Recent incarceration, Substance Use, Overdose, and Service Use among people who Use drugs in Rural communities. JAMA Netw Open. 2023;6(11):e2342222.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"519_CR37","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1080\/08897077.2022.2060449","volume":"43","author":"A Werremeyer","year":"2022","unstructured":"Werremeyer A, Strand MA, Eukel H, Skoy E, Steig J, Frenzel O. Longitudinal evaluation of pharmacists\u2019 social distance preference and attitudes toward patients with opioid misuse following an educational training program. Substance Abuse. 2022;43(1):1051\u20136.","journal-title":"Substance Abuse"},{"issue":"4","key":"519_CR38","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/08897077.2021.1900988","volume":"42","author":"A Werremeyer","year":"2021","unstructured":"Werremeyer A, Mosher S, Eukel H, Skoy E, Steig J, Frenzel O, Strand MA. Pharmacists\u2019 stigma toward patients engaged in opioid misuse: when social distance does not mean disease prevention. Substance Abuse. 2021;42(4):919\u201326.","journal-title":"Substance Abuse"},{"issue":"12","key":"519_CR39","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.cptl.2022.10.002","volume":"14","author":"CR Bakos-Block","year":"2022","unstructured":"Bakos-Block CR, Al Rawwad T, Cardenas-Turanzas M, Champagne-Langabeer T. Contact based intervention reduces stigma among pharmacy students. Currents Pharm Teach Learn. 2022;14(12):1471\u20137.","journal-title":"Currents Pharm Teach Learn"},{"issue":"5","key":"519_CR40","first-page":"28","volume":"46","author":"CM Bookwalter","year":"2021","unstructured":"Bookwalter CM. Challenges in community pharmacy during COVID-19: the perfect storm for personnel burnout. US Pharm. 2021;46(5):28\u201331.","journal-title":"US Pharm"},{"issue":"4","key":"519_CR41","first-page":"10","volume":"6","author":"J Chen","year":"2023","unstructured":"Chen J, Cho SL. Shortages persist in an Evolving Profession. Pharm Times. 2023;6(4):10\u20131. https:\/\/www.pharmacytimes.com\/view\/shortages-persist-in-an-evolving-profession.","journal-title":"Pharm Times"},{"issue":"8","key":"519_CR42","first-page":"20","volume":"8","author":"T Trygstad","year":"2022","unstructured":"Trygstad T, SBIRT Spells Cornerstone of Future Pharmacy Practice. Pharm Times. 2022;8(8):20\u20131. https:\/\/www.pharmacytimes.com\/view\/sbirt-spells-cornerstone-of-future-pharmacy-practice.","journal-title":"Pharm Times"},{"issue":"2","key":"519_CR43","doi-asserted-by":"publisher","first-page":"e13122","DOI":"10.1016\/j.heliyon.2023.e13122","volume":"9","author":"N Scheinberg","year":"2023","unstructured":"Scheinberg N, Andersen R, Gruver M, Kim SH. Substance misuse training in pharmacy education: results from a pilot study on the integration of an interprofessional experience. Heliyon. 2023;9(2):e13122.","journal-title":"Heliyon"},{"issue":"1","key":"519_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.sapharm.2015.07.003","volume":"12","author":"PC Hardigan","year":"2016","unstructured":"Hardigan PC, Popovici I, Carvajal MJ. Response rate, response time, and economic costs of survey research: a randomized trial of practicing pharmacists. Res Social Administrative Pharm. 2016;12(1):141\u20138.","journal-title":"Res Social Administrative Pharm"},{"issue":"4","key":"519_CR45","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.japh.2018.04.025","volume":"58","author":"SE Rudolph","year":"2018","unstructured":"Rudolph SE, Branham AR, Rhodes LA, Moose JS, Marciniak MW. Identifying barriers to dispensing naloxone: a survey of community pharmacists in North Carolina. J Am Pharmacists Association. 2018;58(4):S55\u20138.","journal-title":"J Am Pharmacists Association"},{"key":"519_CR46","doi-asserted-by":"crossref","unstructured":"Salwan A, Hagemeier NE, Tudiver F, Dowling-McClay K, Foster KN, Arnold J, Alamian A, Pack RP. Community pharmacist engagement in opioid use disorder prevention and treatment behaviors: A descriptive analysis. J Am Pharm Assoc (2003). 2020 Nov-Dec;60(6):e173-e178.","DOI":"10.1016\/j.japh.2020.06.008"},{"issue":"1","key":"519_CR47","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.sapharm.2015.08.008","volume":"12","author":"N Shcherbakova","year":"2015","unstructured":"Shcherbakova N. The delivery mode matters when surveying US practicing pharmacists: the reason to say\u2019no\u2019to the hybrid method. Res Social Administrative Pharmacy: RSAP. 2015;12(1):169\u201370.","journal-title":"Res Social Administrative Pharmacy: RSAP"},{"issue":"4","key":"519_CR48","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1093\/ajhp\/zxaa389","volume":"78","author":"A Kenney","year":"2021","unstructured":"Kenney A, Cox N, Bryan MA, Cochran G. Brief intervention medication therapy management: establishment of an opioid misuse intervention model delivered in a community pharmacy. Am J Health Syst Pharm. 2021;78(4):310\u20139.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"519_CR49","first-page":"24","volume":"45","author":"D Rao","year":"2024","unstructured":"Rao D, McAtee C, Mercy M, Shiyanbola OO, Ford JH 2. Nd. An implementation-focused qualitative exploration of Pharmacist needs regarding an opioid use disorder screening and brief intervention. Subst Use Addctn J. 2024;45(1):24\u201332.","journal-title":"Subst Use Addctn J"},{"issue":"5","key":"519_CR50","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.japh.2023.06.001","volume":"63","author":"JA Adams","year":"2023","unstructured":"Adams JA, Chopski NL, Adams AJ. Opportunities for pharmacist prescriptive authority of buprenorphine following passage of the mainstreaming addiction treatment (MAT) act. J Am Pharmacists Association. 2023;63(5):1495\u20139.","journal-title":"J Am Pharmacists Association"},{"issue":"4","key":"519_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/YCO.0000000000000943","volume":"37","author":"A Cheetham","year":"2024","unstructured":"Cheetham A, Grist E, Nielsen S. Pharmacist-prescriber collaborative models of care for opioid use disorder: an overview of recent research. Curr Opin Psychiatry. 2024;37(4):251\u20137.","journal-title":"Curr Opin Psychiatry"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00519-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00519-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00519-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T01:02:53Z","timestamp":1733101373000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00519-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["519"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00519-w","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Duke University Health System Institutional Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}